ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Protocol biopsy"

  • 2022 American Transplant Congress

    Plasmapheresis and Rituximab for Prevention of Focal Segmental Glomerulosclerosis Recurrence Post-Kidney Transplantation

    A. N. Yun1, A. W. Rogers1, J. C. Krisl1, A. Kagan2, H. E. Adrogue2, A. J. Khan2, P. Khairallah2, S. G. Yi3, M. J. Hobeika3, R. R. McMillan3, H. Podder3, A. O. Gaber3, R. J. Knight3

    1Pharmacy, Houston Methodist Hospital, Houston, TX, 2Nephrology, Houston Methodist Hospital, Houston, TX, 3Surgery, Houston Methodist Hospital, Houston, TX

    *Purpose: Primary focal segmental glomerulosclerosis (FSGS) recurs after kidney transplantation (KT) in 30-50% of recipients with a median time of 1.5 months post-KT. Recurrence is…
  • 2022 American Transplant Congress

    Performance of Donor Derived Cell Free DNA (dd-cfDNA) in Diagnosing Subclinical and Clinical Acute Rejection in Kidney Transplant Recipients

    T. Cober, P. West-Thielke, C. Miller, N. Grund, M. Altrich, A. Sutton, R. Sinha, M. Miller, S. Kleiboeker, J. Weems

    Eurofins, Framingham, MA

    *Purpose: The aim of this study was to examine the performance of Viracor TRAC donor derived cell free DNA (dd-cfDNA) in for-cause biopsies as well…
  • 2022 American Transplant Congress

    Trends in Donor Derived Cell Free DNA Before and After Cellular and Antibody Mediated Rejection

    K. Guo1, J. Friedewald1, C. Rebello1, B. Kinsella1, S. Park2, L. Zhao1

    1Northwestern University, Chicago, IL, 2Transplant nephrology, Northwestern University, Chicago, IL

    *Purpose: The TRAC dd-cfDNA test was developed to detect acute kidney transplant rejection but can also detect subclinical rejection with improved performance in antibody-mediated rejection…
  • 2022 American Transplant Congress

    Tissue Engineering Scaffolds for Minimally Invasive Immunosurveillance of Acute Cellular Graft Rejection

    R. R. Urie1, D. Farris2, A. Morris1, E. Lombard1, J. Z. Li3, D. Goldstein2, L. Shea1

    1Biomedical Engineering, University of Michigan, Ann Arbor, MI, 2Internal Medicine, University of Michigan, Ann Arbor, MI, 3Human Genetics, University of Michigan, Ann Arbor, MI

    *Purpose: As there is no assay to predict the risk of acute cellular allograft rejection (ACAR), clinicians rely on protocol graft biopsy and aggressive, one-size-fits-all…
  • 2022 American Transplant Congress

    Two-Week Protocol Biopsy in Renal Allograft: Feasibility, Safety, and Outcomes

    M. Lim1, K. Lee2

    1Samsung Medical Center, Seoul, Korea, Republic of, 2Department of Surgery, Samsung Medical Center, Seoul, Korea, Republic of

    *Purpose: Protocol biopsy in renal allograft helps to early detect subclinical rejection (SCR) in patients who have no abnormal clinical and laboratory findings. Still, there…
  • 2022 American Transplant Congress

    Very Low Frequency of Pathological Findings in One-Year Protocol Biopsies of Low-Risk Kidney Transplant Recipients – Results from the Nordic Protocol Biopsy Study

    I. Helanterä1, C. Dörje2, F. Ortiz3, A. Varberg Reisæter2, C. Hammarstrøm2, J. Lauronen4, A. Räisänen-Sokolowski5, A. J. Haugen6, M. Lempinen1, A. Åsberg2, G. Mjøen2

    1Transplantation and Liver Surgery, Helsinki University Hospital, Helsinki, Finland, 2Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway, 3Nephrology, Helsinki University Hospital, Helsinki, Finland, 4Histocompatibility Laboratory, Finnish Red Cross Blood Service, Helsinki, Finland, 5Department of Pathology, Helsinki University Hospital, Helsinki, Finland, 6Medical Department, Bærum Hospital, Bærum, Norway

    *Purpose: The clinical usefulness of kidney graft protocol biopsies have been debated. We studied the frequency of borderline and T-cell-mediated rejection (TCMR) in one-year protocol…
  • 2022 American Transplant Congress

    Surveillance with Protocol Biopsies for Rejection Significantly Impacts Survival Following Intestine Transplant

    J. R. Sherwood1, Y. Ichkhanian2, N. Beltran3, S. Nagai3, S. Jafri4

    1Wayne State School of Medicine, Detroit, MI, 2Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, 3Department of Transplant Surgery, Henry Ford Hospital, Detroit, MI, 4Division of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI

    *Purpose: Frequent surveillance biopsy is required on the first month post intestinal transplant(IT) due to high-risk of acute rejection. However, the utility and the frequency…
  • 2021 American Transplant Congress

    A Reliable Non Invasive Alternative to Surveillance Renal Allograft Biopsy

    R. Jain, S. Thaduri, V. Kumar, C. Kew, B. Julian, G. Towns, S. Ong, F. Ahmed, S. Mehta, G. Agarwal

    Transplant Nephrology, University of Alabama Birmingham, Birmingham, AL

    *Purpose:Surveillance Renal Allograft Biopsy (SAVB) is the standard of care to identify subclinical immunological injury(SCI). However fewer than 25% of transplant centers in the US…
  • 2020 American Transplant Congress

    Impact of Variation in Histological Assessments and Their Impact on Clinical Trial Enrollment and Endpoints – Preliminary Report of The Gen04 Study

    W. Park1, M. Ryan2, L. Herrera Hernandez3, M. Smith2, X. Geiger4, T. Sandor5, L. Cornell3, M. Stegall1

    1Transplant Center, Mayo Clinic, Rochester, MN, 2Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, 3Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 4Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, 5Pathology, University of Szegad, Szegad, Hungary

    *Purpose: Renal allograft histology is often used as inclusion criteria for clinical trials. This includes Gen04, which is an NIH sponsored multi-center clinical trial involving…
  • 2020 American Transplant Congress

    Cost-Effectiveness of Protocol Biopsies in Kidney Transplantation

    C. M. Puttarajappa, S. Hariharan, K. J. Smith

    Medicine, University of Pittsburgh, Pittsburgh, PA

    *Purpose: To perform an economic evaluation of protocol biopsies in kidney transplantation*Methods: We used a Markov decision analytical model (Figure 1) to compare the following…
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences